These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 12073167)
1. Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels. Radu D; Ahlin A; Svanborg P; Lindefors N Psychopharmacology (Berl); 2002 Jun; 161(4):396-403. PubMed ID: 12073167 [TBL] [Abstract][Full Text] [Related]
2. Pentagastrin test for anxiety--psychophysiology and personality. Radu D; Ahlin A; Svanborg P; Lindefors N Psychopharmacology (Berl); 2003 Mar; 166(2):139-45. PubMed ID: 12529809 [TBL] [Abstract][Full Text] [Related]
3. Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Abelson JL; Liberzon I Neuropsychopharmacology; 1999 Oct; 21(4):485-94. PubMed ID: 10481831 [TBL] [Abstract][Full Text] [Related]
4. The effects of central administration of the CCK-B receptor agonist pentagastrin on feeding and cortisol release in sheep. Ebenezer IS; Parrott RF Methods Find Exp Clin Pharmacol; 1996 May; 18(4):235-8. PubMed ID: 8803955 [TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin and panic disorder: past and future clinical research strategies. Bradwejn J; Koszycki D Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976 [TBL] [Abstract][Full Text] [Related]
6. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Abelson JL; Le Mellédo J; Bichet DG Neuropsychopharmacology; 2001 Feb; 24(2):161-9. PubMed ID: 11120398 [TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori. Konturek JW J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215 [TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Lines C; Challenor J; Traub M Br J Clin Pharmacol; 1995 Mar; 39(3):235-42. PubMed ID: 7619662 [TBL] [Abstract][Full Text] [Related]
9. Effects of propranolol on symptom and endocrine responses to pentagastrin. Khan S; Liberzon I; Abelson JL Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640 [TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-mediated inhibition of transmembrane signalling through CCK(A) and CCK(B) receptors. Smeets RL; Fouraux MA; van Emst-de Vries SE; De Pont JJ; Willems PH Br J Pharmacol; 1998 Mar; 123(6):1189-97. PubMed ID: 9559904 [TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682 [TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Béhé M; Behr TM Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727 [TBL] [Abstract][Full Text] [Related]
13. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. McCann UD; Slate SO; Geraci M; Uhde TW Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584 [TBL] [Abstract][Full Text] [Related]
14. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system. Sherrin T; Todorovic C; Zeyda T; Tan CH; Wong PT; Zhu YZ; Spiess J Mol Psychiatry; 2009 Mar; 14(3):291-307. PubMed ID: 18195718 [TBL] [Abstract][Full Text] [Related]
15. Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin. Khan S; Liberzon I; Abelson JL Psychiatry Res; 2004 May; 126(3):189-95. PubMed ID: 15157745 [TBL] [Abstract][Full Text] [Related]
16. Opposite effects of CCK(B) agonists in grooming behaviour in rats: further evidence for two CCK(B) subsites. Ladurelle N; Sebret A; Garbay C; Roques BP; Daugé V Br J Pharmacol; 1998 Jul; 124(6):1091-8. PubMed ID: 9720778 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and respiratory responses to a panicogenic agent in anaesthetised female Wistar rats at different stages of the oestrous cycle. Brack KE; Jeffery SM; Lovick TA Eur J Neurosci; 2006 Jun; 23(12):3309-18. PubMed ID: 16820020 [TBL] [Abstract][Full Text] [Related]
18. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Spina MG; Merlo-Pich E; Akwa Y; Balducci C; Basso AM; Zorrilla EP; Britton KT; Rivier J; Vale WW; Koob GF Psychopharmacology (Berl); 2002 Mar; 160(2):113-21. PubMed ID: 11875628 [TBL] [Abstract][Full Text] [Related]
19. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119 [TBL] [Abstract][Full Text] [Related]
20. Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and meal-stimulated plasma gastrin release in the absence of peptic ulcer disease. Hurlimann S; Dür S; Schwab P; Varga L; Mazzucchelli L; Brand R; Halter F Am J Gastroenterol; 1998 Aug; 93(8):1277-85. PubMed ID: 9707051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]